Related Experiment Videos
Outcome of moderate aplastic anemia in children
1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Insights
Children with moderate aplastic anemia (MAA) have an excellent prognosis, with most recovering with minimal or no treatment. Those progressing to severe aplastic anemia (SAA) responded well to therapy, showing significantly better survival than SAA patients.
Area of Science:
- Pediatric Hematology
- Bone Marrow Failure Syndromes
- Aplastic Anemia Research
Background:
- Moderate aplastic anemia (MAA) requires clear management strategies for pediatric patients.
- Distinguishing MAA from severe aplastic anemia (SAA) is crucial for treatment and prognosis.
- Understanding the natural history of MAA is essential for guiding clinical decisions.
Purpose of the Study:
- To review the clinical course and outcomes of pediatric patients diagnosed with moderate aplastic anemia (MAA).
- To compare the outcomes of children with MAA to those with severe aplastic anemia (SAA).
- To inform the management of newly diagnosed children with MAA.
Main Methods:
- Retrospective review of 12 children with MAA and 28 with SAA over 12 years.
- MAA defined by hypocellular bone marrow and cytopenia in at least two cell lines (not severe).
- MAA patients received immunomodulation (antithymocyte globulin and/or cyclosporine) if they progressed to SAA.
Main Results:
- Five MAA patients progressed to SAA at a median of 18 months; seven required no or minimal transfusion support.
- MAA patients demonstrated significantly better survival than SAA patients treated with immunomodulation (p=0.022).
- All MAA patients were alive at 7-year follow-up, transfusion-independent, with only one requiring ongoing therapy.
Conclusions:
- Pediatric MAA has an excellent outcome, superior to SAA, with over half recovering spontaneously.
- MAA patients who progressed to SAA responded favorably to immunomodulatory treatment.
- Further prospective studies are warranted to fully elucidate the natural history of pediatric MAA.
Purpose:
In order to assist in the management of newly diagnosed children with moderate aplastic anemia (MAA) we reviewed the clinical course and outcome of children with MAA seen at our institution over the past 12 years and compared them with children with severe aplastic anemia (SAA).
Patients And Methods:
MAA was defined as having a hypocellular bone marrow and cytopenia in at least two cell lines not in the severe range. Twelve children met these criteria. Twenty-eight children with SAA were seen during the same interval. Patients with MAA were treated with immunomodulation with antithymocyte globulin and/or cyclosporine if they progressed to SAA.
Results:
Five patients with MAA progressed to SAA at a median interval of 18 months from diagnosis. The other seven patients required no therapy or only received transfusions for < or = 6 months after diagnosis. The survival of the patients with MAA was significantly better than that of patients with SAA treated with immunomodulation (p = 0.022). All patients with MAA are alive at a median follow up of 7 years and are transfusion independent; only one patient currently receives therapy. Residual hematologic abnormalities in children with MAA included thrombocytopenia, leukopenia, and macrocytosis.
Conclusions:
In this small series of children with MAA the outcome was excellent and significantly better than in patients with SAA; more than half recovered with minimal or no therapy. Patients who progressed to SAA responded well to treatment. A larger prospective study is needed to conclusively define the natural history of MAA.